Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

December 5, 2019December 5, 2019

Taltz Eases Disease Activity, Improves Quality of Life in nr-axSpA Patients, Phase 3 Trial Shows

News

Treatment with the anti-rheumatic drug Taltz (ixekizumab) leads to early and sustained reductions in pain, fatigue, and inflammation in people with non-radiographic axial spondyloarthritis (nr-axSpA), a Phase 3 trial ... Read more

November 25, 2019November 25, 2019

Cosentyx Reduces Disease Activity and Pain in nr-axSpA Patients, Phase 3 Trial Shows

News

Treatment with Cosentyx (secukinumab) provided stable reduction in disease activity, as well as less pain and better mobility in people with non-radiographic axial spondyloarthritis (nr-axSpA), a Phase 3 trial ... Read more

November 7, 2019November 7, 2019

Continuous Use of NSAIDs Increases Hypertension Risk in AS Patients, Study Suggests

News

Continuous use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hypertension by 12% in people with ankylosing spondylitis (AS), a prospective study suggests. The study, “Nonsteroidal Anti-inflammatory Drug ... Read more

November 4, 2019November 4, 2019

Women Stop Using TNF Inhibitors Earlier and Switch More Often Than Do Men, Dutch Study Reports

News

Women with ankylosing spondylitis (AS) stay with TNF inhibitor treatment for significantly shorter periods than men, mostly due to ineffectiveness, and they are at higher risk of developing infections while on ... Read more

October 21, 2019October 21, 2019

Xeljanz Reduces Spinal Inflammation in One-third of AS Patients, Phase 2 Trial Shows

News

Treatment with Xeljanz (tofacitinib citrate) led to a clinically meaningful reduction in spinal and sacroiliac joint inflammation in approximately one-third of ankylosing spondylitis (AS) patients taking part in a ... Read more

October 7, 2019October 7, 2019

Cosentyx Effectively Lowers Disease Activity in nr-axSpA Patients Treated for 1 Year, Phase 3 Trial Reports

News

Treatment with Novartis’ Cosentyx (secukinumab) significantly reduced disease activity compared to placebo in patients with non-radiographic axial spondyloarthritis (nr-axSpA), according to new data from the Phase 3 PREVENT trial. The ... Read more

September 23, 2019September 23, 2019

Cosentyx Shows Promise in Managing nr-axSpA Disease Activity, Phase 3 Trial Shows

News

Treatment with Novartis’ Cosentyx (secukinumab) led to a significant reduction in disease activity compared to placebo in patients with non-radiographic axial spondyloarthritis (nr-axSpA), according to results from the ongoing Phase 3 PREVENT trial. ... Read more

August 5, 2019August 5, 2019

Yisaipu, Biosimilar of Enbrel, Will be Available as Pre-filled Syringe in China

News

Yisaipu, a biosimilar of Enbrel (etanercept), has been approved in China as a pre-filled syringe to treat ankylosing spondylitis, among other conditions, announced the treatment’s developer, Sunshine Guojian Pharmaceutical, ... Read more

July 29, 2019July 29, 2019

FDA Approves Humira Biosimilar Hadlima for Treatment of Ankylosing Spondylitis

News

Hadlima (adalimumab-bwwd), a biosimilar to AbbVie’s Humira, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ankylosing spondylitis. The therapy was also approved ... Read more

June 17, 2019June 17, 2019

‘Multimorbidity’ More Likely in Axial Spondyloarthropathy, Linked to Worse Outcomes, Irish Study Finds

News

People with axial spondyloarthropathy are more prone to develop additional disorders — called “multimorbidity” — which is associated with worse disease outcomes, according to a recent Irish study. The ... Read more

Pin It on Pinterest